
ShenZhen Geno-immune Medical Institute (GIMI) was established in 2015 and funded by the Municipal Government of Shenzhen. GIMI faculty and team focus on translational research of medicine, particularly cell-based immunotherapies and gene therapies.
Headed by Professor Dr. Lung-Ji Chang, GIMI also retains several international leading scientists with pioneering expertise in molecular biology, medicine, translational trials, and biomedical innovation.
GIMI has accumulated a large sum of encouraging results with its 4th generation CAR-T technologies in treating late stage cancers. So far, more than 1000 cancer patients (both domestic and overseas) have received treatment through GIMI’s coordination based on the advanced CAR-T technologies.